Evidence map›Paper›PMID 40909513›Full record

ArticlebioRxiv : the preprint server for biology2025

Phenotypic screening converges on CDK9 inhibition as a therapeutic strategy in translocation renal cell carcinoma.

Dharma R Thapa, Riva Deodhar, Adam Skepner, Prathyusha Konda, Meng Zhou, Joseph Bluck, Christian Pichlo, Yantong Cui, Paige Stocker, Prateek Khanna and 10 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Dharma R ThapaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Riva DeodharDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Adam SkepnerCenter for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA.
Prathyusha KondaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Meng ZhouResearch and Innovation Center, Bayer U.S. LLC, Cambridge, MA 02142, USA.
Joseph BluckStructural Biology and Computational Design, Bayer AG, 13342 Berlin, Germany.
Christian PichloStructural Biology and Computational Design, Bayer AG, 40789 Monheim am Rhein, Germany.
Yantong CuiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Paige StockerCenter for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA.
Prateek KhannaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Jiao LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Jonathan M TsaiDepartment of Pathology, Brigham and Women's Hospital, Boston, MA 02215, USA.
Alison LeedCenter for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA.
Sandy GouldCenter for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA.
Maria AlimovaCenter for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA.
Dhana FriedrichChemical Biology, Imaging & Omics, Bayer AG, 42113 Wuppertal, Germany.
Jaime H CheahCenter for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA.
Rajesha RupaimooleResearch and Innovation Center, Bayer U.S. LLC, Cambridge, MA 02142, USA.
Oivin GuicheritCenter for the Development of Therapeutics, Broad Institute, Cambridge, MA 02142, USA.
Srinivas R ViswanathanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Funding

Probing the role of somatic X-chromosome alterations in shaping cancer sex differencesR01CA286652 · NCI · DANA-FARBER CANCER INST · PI VISWANATHAN, SRINIVAS RAGHAVAN, ZHANG, CHENG-ZHONG · 2023 to 2025
$2.7M
Molecular mechanisms and therapeutic targeting of activated NRF2 signaling in MiT/TFE translocation renal cell carcinomaR01CA279044 · NCI · DANA-FARBER CANCER INST · PI Srinivas Raghavan Viswanathan · 2023 to 2026
$2.0M
NCI NIH HHS R01 CA279044NCI NIH HHS R01 CA286652
6 · The paper itself

Abstract

Translocation renal cell carcinoma (tRCC) is an aggressive kidney cancer driven by gene fusions of the

Identifiers

PMID40909513
PMCPMC12407813

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.